Patent prosecution does not end when you overcome an office action. The most valuable patent portfolios are built through deliberate use of continuation practice, divisional applications, and coordinated multi-office prosecution -- tools that allow you to extract maximum protection from a single disclosure. This chapter covers the advanced procedural mechanisms that experienced practitioners use to build layered claim coverage, maintain prosecution flexibility, and adapt patent portfolios to evolving business and competitive landscapes.
Continuation Applications
A continuation application is a new patent application filed while a parent application is still pending (copendency is required), claiming the same priority date and relying on the identical specification. The continuation contains no new disclosure -- it simply pursues different claims based on the same written description.
Why File Continuations
Continuations serve several strategic purposes that go well beyond "trying again" after a rejection:
- Broadening claim scope. If the parent application issues with narrow claims, a continuation allows you to pursue broader claims that may cover competitor implementations you did not anticipate when drafting the original claims.
- Adapting to market changes. Products and competitive landscapes evolve. A continuation lets you craft claims directed at how competitors are actually implementing the technology, rather than how you predicted they would at the time of original filing.
- Preserving prosecution flexibility. By filing a continuation before the parent issues, you keep the prosecution chain alive. This gives you the ability to file further continuations, respond to new prior art, or pursue claims in different technological directions -- all while maintaining the original priority date.
- Separating claim strategies. You may want one patent with broad apparatus claims and another with narrow method claims directed at a specific use case. Continuations allow you to pursue these in parallel without the claim count and complexity issues that arise from having too many claims in a single application.
Copendency Requirement
A continuation must be filed while the parent application is pending. In practice, this means filing the continuation before -- or simultaneously with -- payment of the issue fee on the parent. Once the parent issues as a patent, you cannot file a continuation claiming its priority. This is a strict deadline: if you miss it, the chain is broken.
Do not let the chain die unintentionally. Many practitioners docket a standing reminder to evaluate continuation filing every time a parent application receives a Notice of Allowance. The decision to file or not file a continuation should be affirmative and documented, not a deadline that slips by.
Continuation Filing Mechanics
| Element | Requirement |
|---|---|
| Specification | Identical to the parent (no new matter) |
| Claims | New claims; can be broader, narrower, or differently directed than the parent |
| Priority claim | Must reference the parent application in the Application Data Sheet (ADS) |
| Copendency | Must be filed while the parent is pending |
| Filing fees | Same as a new nonprovisional application (filing, search, examination) |
| Examination | Examined independently; may be assigned to a different examiner |
Continuation-in-Part Applications
A continuation-in-part (CIP) adds new matter to the parent disclosure. The CIP includes everything from the parent specification plus additional subject matter -- new experimental data, new embodiments, or new technical approaches developed after the parent was filed.
Priority Implications
The CIP's priority structure is bifurcated:
- Claims supported entirely by the parent specification receive the parent's priority date.
- Claims that rely on the new matter receive only the CIP's own filing date as their effective priority date.
This distinction is critical for prior art analysis. Any reference published between the parent's filing date and the CIP's filing date can be used against claims that depend on new matter, but not against claims fully supported by the parent disclosure.
When to Use a CIP Versus a New Application
CIPs are appropriate when you want to maintain the priority chain for original claims while also protecting improvements. However, CIPs have significant drawbacks that make many practitioners prefer filing an entirely new application:
- The bifurcated priority date creates analytical complexity during prosecution and litigation.
- Examiners and courts must determine, claim by claim, which priority date applies -- which introduces uncertainty.
- The new matter in a CIP cannot benefit from the original priority date, so if timing matters (for example, if intervening prior art exists), a CIP may not provide the protection you expect.
- A new standalone application with its own priority date is often cleaner and avoids the confusion of dual-dated claims.
Divisional Applications
A divisional application arises when an examiner determines that a single application contains claims directed to more than one distinct invention. The applicant is required to elect one invention for prosecution in the parent application and can pursue the non-elected inventions through divisional applications.
USPTO Restriction Requirements
At the USPTO, the examiner issues a restriction requirement under 35 U.S.C. 121 when the application contains claims to two or more independent and distinct inventions. The examiner identifies the distinct invention groups and requires the applicant to elect one group for prosecution.
| Restriction Basis | Description | Example |
|---|---|---|
| Independent inventions | Inventions that are unrelated in design, operation, or effect | A chemical compound and a machine for manufacturing it, where the compound can be made by other processes |
| Distinct inventions | Inventions that are related but patentably distinct | An apparatus and a method of using it, where the apparatus could be used in other ways |
| Species election | Multiple species of a single genus are claimed | Claims to specific chemical structures within a broader Markush group |
Traversal. You are not required to accept a restriction requirement. You can traverse (disagree with) the requirement by arguing that the inventions are not independent or distinct, or that searching them together would not impose an undue burden. However, traversals rarely succeed -- examiners have broad discretion in this area.
Election with traverse preserves your rights. If you elect an invention group but traverse the restriction, you preserve the right to petition if you later believe the restriction was improper. If you elect without traverse, you accept the restriction and waive the right to challenge it.
EPO Unity of Invention
The EPO applies a different but related concept: unity of invention under Article 82 EPC. Rather than asking whether inventions are "independent and distinct" (the USPTO standard), the EPO asks whether the claims involve "one invention or a group of inventions so linked as to form a single general inventive concept."
The EPO's approach is based on the presence of a common special technical feature -- a feature that makes a contribution over the prior art and is shared across all claimed inventions. If no such feature exists, the examining division issues an objection of lack of unity and invites the applicant to restrict the claims.
| Aspect | USPTO Restriction | EPO Unity of Invention |
|---|---|---|
| Legal basis | 35 U.S.C. 121 | Article 82 EPC |
| Standard | Independent and distinct inventions | Single general inventive concept |
| Key test | Separate classification, separate search burden | Common special technical feature |
| Timing | Usually before substantive examination | Can arise during search or examination |
| Consequence | Must elect one group; file divisionals for others | Must restrict claims; file divisionals for others |
| Search fee impact | No additional search fee for elected invention | Additional search fee required for each non-unitary group |
Strategic Use of Divisionals
Divisionals are not merely a procedural response to a restriction requirement -- they can be a deliberate portfolio strategy:
- Layered coverage. File divisionals directed at different aspects of the technology (apparatus, method, system, data structure) to create a portfolio that is difficult to design around.
- Timing. At the EPO, a divisional can be filed at any time while the parent application is pending. This creates opportunities to file divisionals strategically -- for example, after seeing how competitors implement the technology.
- Maintaining pendency. Like continuations in the U.S., divisionals can keep prosecution alive. A chain of parent-divisional-divisional applications extends the window for adapting claims to the competitive landscape.
Request for Continued Examination
Chapter 10 introduced the RCE as a response to final rejection. Here, we examine RCE strategy in the context of broader prosecution planning.
RCE Versus Continuation Versus Appeal
The decision among these three paths after final rejection involves trade-offs in cost, timing, examiner dynamics, and claim scope.
| Factor | RCE | Continuation | Appeal (PTAB) |
|---|---|---|---|
| Cost (large entity) | ~$2,640 fee + attorney time | ~$2,000-$3,000 filing fees + attorney time | ~$2,000 appeal fee + brief preparation |
| Timeline | 3-12 months to next action | 12-24 months to first action (new examination queue) | 12-24 months to PTAB decision |
| Examiner | Same examiner continues | May get a different examiner | Reviewed by PTAB judges |
| Claim scope | Same claims or narrowed | Can pursue broader or different claims | Limited to claims on appeal |
| Prosecution record | Adds to existing record | Fresh record on the new claims | Appellate record created |
| Strategic signal | Signals willingness to work with examiner | Signals fresh start | Signals confidence in legal position |
The two-RCE rule of thumb. Many experienced practitioners follow an informal guideline: after two RCEs with the same examiner on the same set of issues, the likelihood of a different outcome diminishes sharply. At that point, the case is usually better served by an appeal (if the legal position is strong) or a continuation with a fresh claim set (if the issue is framing rather than substance).
RCE Timing and Patent Term Adjustment
Every RCE resets the clock on certain patent term adjustment (PTA) calculations. Under current USPTO rules, applicant delay attributable to an RCE filing can reduce the PTA you would otherwise receive. If you are tracking PTA carefully -- for example, in pharmaceutical cases where even a few days of additional patent term can be worth millions -- the decision to file an RCE must account for its impact on the final patent term.
Double Patenting and Terminal Disclaimers
When the same inventor or assignee files multiple applications with overlapping claim scope, the doctrine of double patenting prevents the same invention from being patented twice.
Types of Double Patenting
Statutory (same-invention) double patenting. Under 35 U.S.C. 101, you cannot obtain two patents with identical claims. This is rare in practice because claims are almost never literally identical across applications.
Obviousness-type double patenting (ODP). This is the far more common form. ODP applies when the claims of a later-filed application are not patentably distinct from (i.e., are obvious variations of) the claims of an earlier-filed application or issued patent by the same inventor or assignee. ODP is a judicially created doctrine designed to prevent unjustified extensions of patent term through serial filing of obvious variations.
Terminal Disclaimers
The standard mechanism for overcoming an ODP rejection is filing a terminal disclaimer. A terminal disclaimer:
- Disclaims the terminal portion of the later patent's term so it expires on the same date as the earlier patent.
- Requires that the later patent be commonly owned with the earlier patent throughout its life.
- Is irrevocable once filed.
How a terminal disclaimer aligns patent expiration dates to overcome an ODP rejection
Strategic Considerations
Terminal disclaimers tie the fates of related patents together. If the earlier patent is invalidated, the later patent may also be affected. This creates portfolio risk that must be weighed against the benefit of obtaining the additional patent.
Recent developments in U.S. patent law have increased scrutiny of terminal disclaimers. The USPTO's 2024 terminal disclaimer rule requires the disclaiming party to agree that the later patent is unenforceable if the earlier patent's claims are found unpatentable or invalid. This means filing a terminal disclaimer is no longer a routine procedural step -- it carries meaningful enforcement risk.
| Consideration | Implication |
|---|---|
| Linked expiration dates | Both patents expire on the same date, eliminating any term extension benefit |
| Common ownership requirement | Licensing or assigning one patent independently becomes more complex |
| Invalidation linkage | Under the 2024 rule, invalidation of the earlier patent can render the later patent unenforceable |
| Irrevocability | Once filed, the terminal disclaimer cannot be withdrawn |
Patent Term Adjustment
The USPTO compensates patent holders for delays in prosecution that are attributable to the office itself. This compensation takes the form of patent term adjustment (PTA), which extends the patent term beyond the standard 20 years from the earliest U.S. nonprovisional filing date.
How PTA Is Calculated
PTA is calculated under 35 U.S.C. 154(b) based on three categories of delay:
A Delay (14-month guarantee). The USPTO guarantees that it will issue a first office action within 14 months of filing. Each day of delay beyond 14 months adds one day of PTA.
B Delay (3-year guarantee). The USPTO guarantees that it will issue a patent within three years of the nonprovisional filing date (excluding certain applicant-caused delays, RCE processing time, and interference/derivation proceedings). Each day of delay beyond three years adds one day of PTA.
C Delay (specific deadlines). The USPTO must act within four months on replies, appeals, and interference decisions, and must issue a patent within four months of payment of the issue fee. Delays beyond these deadlines add PTA.
Overlap reduction. When A and B delays overlap in time, the overlapping days are subtracted to avoid double-counting.
Applicant delay reduction. PTA is reduced by any period during which the applicant failed to engage in reasonable efforts to conclude prosecution. This includes delays in responding to office actions beyond three months, delays in filing an appeal brief, and the period consumed by each RCE.
Typical PTA Amounts
Average PTA varies significantly by technology center. Applications in congested art units (notably software and business methods) often accumulate substantial B delay. Pharmaceutical and biotechnology applications may receive significant A delay due to examiner workload. Typical PTA ranges from zero to several hundred days, though PTA exceeding 1,000 days is not unheard of in certain art units.
PTA disputes are common and worth pursuing. The USPTO's automated PTA calculation system occasionally makes errors, particularly in computing applicant delay reductions. Applicants have two months from patent issuance to request reconsideration of PTA, and can file a civil action in the Eastern District of Virginia within 180 days. For pharmaceuticals and other products with long regulatory approval timelines, even modest PTA corrections can have significant commercial value.
Coordinating Prosecution Across Offices
Filing parallel applications at the USPTO, EPO, and other offices creates opportunities for strategic coordination -- but also introduces complexity. Each office applies different patentability standards, uses different procedural mechanisms, and operates on different timelines.
Harmonizing Claims Across Offices
The temptation is to file identical claims everywhere. In practice, this is rarely optimal. The patentability standards at the USPTO and EPO differ in ways that reward tailored claiming:
| Aspect | USPTO Approach | EPO Approach |
|---|---|---|
| Obviousness / inventive step | Graham v. John Deere factors; motivation to combine; secondary considerations | Problem-solution approach; closest prior art; objective technical problem |
| Software eligibility | Alice/Mayo two-step test; abstract idea analysis | Technical character requirement; further technical effect |
| Claim format | Means-plus-function claims common; functional claiming broadly permitted | Functional features must be supported; two-part claims (characterizing portion) expected |
| Written description | Possession requirement; must show inventor had the invention at filing | Sufficient disclosure; enabling disclosure standard |
| Prior art scope | Includes non-analogous art with documented motivation to combine | Typically limited to the field of the invention or closely related fields |
Practitioners coordinating prosecution across offices should consider filing office-specific claim sets that account for these differences. For example, claims at the EPO might emphasize the technical problem solved and use the two-part form that examiners expect, while claims at the USPTO might be drafted more broadly and rely on functional language.
Using Patent Prosecution Highway (PPH) Results
The Patent Prosecution Highway allows applicants to request accelerated examination at a second office based on favorable work product from a first office. If the USPTO allows certain claims, you can use those results to request fast-track examination at the EPO (and vice versa), or at the JPO, KIPO, CNIPA, and dozens of other participating offices.
PPH strategy considerations:
- First-office selection matters. If the USPTO allows broad claims, you can use those results to request PPH at the EPO. However, the EPO examiner is not bound by the USPTO's conclusions and will apply EPO standards independently. The PPH accelerates examination -- it does not guarantee the same outcome.
- Claim correspondence. Most PPH programs require that the claims filed at the second office "sufficiently correspond" to the claims allowed at the first office. This does not mean identical claims, but the scope and subject matter must be aligned.
- Timing. PPH requests can be filed at any time before substantive examination begins at the second office. Filing early maximizes the timeline benefit.
Managing Different Procedural Timelines
Typical prosecution timelines at the USPTO and EPO for a patent application filed in January 2024
Key differences in procedural cadence affect strategy:
- The EPO issues a search report with a preliminary opinion on patentability early in the process, giving applicants an informed basis for deciding whether to request examination (which requires a separate fee and decision point). The USPTO searches and examines in a single process.
- EPO examination often begins later than USPTO examination, which means USPTO prosecution results may be available to inform EPO claim strategy.
- The EPO's examination division is a three-examiner panel, whereas the USPTO uses a single primary examiner (with supervisory review). This affects the dynamics of argument and negotiation.
- Divisional filing deadlines differ: at the USPTO, a divisional must be filed while the parent is pending; at the EPO, divisionals can be filed at any time while the parent is pending, including during appeal.
Practical Coordination Workflow
The most effective approach to multi-office prosecution follows a sequence:
- File first at the office most likely to produce favorable results. This is often the office with the most permissive standard for your technology area (e.g., the EPO for mechanical inventions, the USPTO for software).
- Use early prosecution results to refine claims at other offices. If the first office's search report identifies relevant prior art, adjust claims at other offices before examination begins.
- Leverage PPH where appropriate. Once claims are allowed at one office, request accelerated examination at participating offices.
- Maintain office-specific claim sets. Do not force identical claims across offices. Tailor claims to each office's standards and the prior art cited in each jurisdiction.
- Coordinate responses. When you amend claims at one office, evaluate whether the same amendment should be made (or avoided) at other offices. Prosecution history created at one office can sometimes be used against you at another.
Frequently Asked Questions
Continuation Practice
Divisionals and Restrictions
Patent Term and Coordination
What's Next
This chapter covered the procedural tools for building and managing a patent prosecution strategy across applications and offices. Chapter 12 moves into the end stage of prosecution: what happens when your patent is granted, the rights you receive, how patent term is calculated, and the maintenance obligations you must meet to keep your patent in force.